NEW APPROACH TO THE PAIN RELIEF IN IRRITABLE BOWEL SYNDROME


I.V. Maev, A.A. Samsonov, A.V. Semenova (Yashina), D.N. Andreev, A.G. Akselrod

Department of Propedeutics of Internal Diseases and Gastroenterology FSBEI HE MSMSU n.a. A.I. Evdokimov of RMH, Moscow
The article presents the results of the comparative non-interventional clinical study in parallel groups aimed to the evaluation of the efficacy and safety of the drug containing a complex of antibodies to tumor necrosis factor α, moskomarhitectura protein S-100, histamine (cAT) compared to trimebutine in the therapy of irritable bowel syndrome (IBS). The data obtained allow to recommend cAT for widespread use in the treatment of IBS, because it will have a positive effect on the relief of the clinical manifestations of the disease, especially pain syndrome.

About the Autors


Corresponding author: A.V. Semenova (Yashina) – Postgraduate Student at the Department of Propedeutics of Internal Diseases and Gastroenterology FSBEI HE MSMSU n.a. A.I. Evdokimov of RMH, Moscow; e-mail: a-lex-ga@yandex.ru


Similar Articles


Бионика Медиа